Literature DB >> 9770335

A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis.

R Keul1, P C Heinrich, G Müller-newen, K Muller, P Woo.   

Abstract

Investigation of the agonist and two antagonists to interleukin 6 (IL-6) and their possible role in the pathogenesis of different sub-groups of juvenile chronic arthritis (JCA). Sera of 54 patients and 10 age-matched controls were tested: 20 with pauci-articular JCA, 12 with polyarticular JCA, and 22 systemic JCA. Interleukin 6, soluble interleukin 6 receptor (agonist), soluble gp130 and autoantibodies to IL-6 (antagonist to IL-6) were measured, as well as C-reactive protein as an indicator of disease activity. In addition, during fever two systemic JCA patients were analysed longitudinally for these parameters. There was a significant increase in soluble IL-6 receptor (sIL-6R) concentrations. No difference in the levels of soluble gp130 and autoantibodies to IL-6 in the systemic JCA group was found. In two patients the fever curves corresponded to the IL-6 levels measured. sIL-6R serum concentrations also showed a tendency to follow the fever. The authors have shown that in systemic JCA, the levels of sIL-6R, agonist of IL-6, were increased significantly compared to the other groups, while levels of antagonists to IL-6 were not changed in the face of increased levels of IL-6 in systemic JCA. These results suggest an imbalance of IL-6 homeostasis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770335     DOI: 10.1006/cyto.1997.0343

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  21 in total

Review 1.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

Review 2.  Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

Authors:  Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau
Journal:  Cytokine Growth Factor Rev       Date:  2008-02       Impact factor: 7.638

Review 3.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity.

Authors:  Kamau Pierre; Naomi Schlesinger; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2016-06-24       Impact factor: 3.107

5.  Cytokines and juvenile idiopathic arthritis.

Authors:  Patricia Woo
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

6.  Circulating interleukin-6 mediates the febrile response to localised inflammation in rats.

Authors:  T Cartmell; S Poole; A V Turnbull; N J Rothwell; G N Luheshi
Journal:  J Physiol       Date:  2000-08-01       Impact factor: 5.182

Review 7.  Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Takako Miyamae; Tomoyuki Imagawa; Shigeki Katakura; Rumiko Kurosawa; Masaaki Mori
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

Review 8.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

9.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

10.  High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.

Authors:  P Pignatti; L Ciapponi; P Galle; M B Hansen; M Massa; C Meazza; G Paonessa; D Novick; G Ciliberto; A Martini; F De Benedetti
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.